Possible patent challenge to Biogen's Tysabri from ipbiz.blogspot.com FiercePharma noted of Biogen's prospects:
India’s Swiss Pharma International has filed a petition for inter partes review of one of Tysabri’s patents--and another two petitions are on the way, Leerink Partners analyst ... Share via E–mail | Twitter | Facebook
The Gatekeeping Function of Patent Eligibility as Part of a More Complete Understanding of § 101 Principles from patentlyo.com Guest Post by Bruce Wexler and Edwin Mok From a review of the opinions expressed in the majority decision and rehearing denial in Ariosa Diagnostics, Inc. v. Sequenom, Inc., 788 F.3d 1371, reh’g ...
Share via E–mail | Twitter | Facebook
The statue of Chief Justice Taney in Baltimore, Dred Scott, and patent law from ipbiz.blogspot.com Of the dispute over the "de-accession" of a statue of former Supreme Court Chief Justice Taney in Baltimore, wherein a mayoral task force has recommended Taney's statue go elsewhere, one does note that Taney ...
Share via E–mail | Twitter | Facebook
WIPO Digital Rightsholders Conference Ponders Business Ideas from www.ip-watch.org Last week’s World Intellectual Property Organization conference on the digital content business gathered speakers from different sectors of industry, from content producers to authors and performers. Rightsholders and others gave updates and tried to ...
Share via E–mail | Twitter | Facebook
Conference & CLE Calendar from www.patentdocs.org April 26, 2016 - Biotechnology/Chemical/Pharmaceutical (BCP) Customer Partnership Meeting (U.S. Patent and Trademark Office) - Alexandria, VA April 27, 2016 - "Patent Prosecution Conflicts of Interest for Clients Having Competing Technologies" (American Intellectual Property Law ...
Share via E–mail | Twitter | Facebook
Court Report from www.patentdocs.org By Sherri Oslick -- About Court Report: Each week we will report briefly on recently filed biotech and pharma cases. Teva Pharmaceuticals USA Inc. et al. v. Biocon Ltd. et al. 1:16-cv-00278; filed April 19 ...
Share via E–mail | Twitter | Facebook